1. Scrip
  2. >>Focus On Asia

Hanmi’s Roll Continues With ZAI China Cancer Deal

 
• By Jung Won Shin

Hanmi is continuing to reap big dividends this year from its original R&D efforts. Following a major licensing out deal with Boehringer Ingelheim for a novel lung cancer therapy in July, the South Korean firm has now reached an additional licensing agreement for the therapy with ZAI Lab for China, Hong Kong and Macau, in a deal that will bolster the Chinese biopharma's growing oncology portfolio.

SEOUL – South Korea’s Hanmi Pharmaceutical Co. Ltd. and ZAI Lab Ltd. have inked a collaboration and license agreement under which the Chinese company will acquire exclusive rights in China, Hong Kong and Macau to develop, manufacture and commercialize HM61713, a novel, third-generation EGFR-targeted therapy for the treatment of EGFR mutation-positive lung cancer being developed by Hanmi.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

 
• By Dexter Jie Yan

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.

Novotech CEO On Flexible Trial Solutions Amid Tariff, Geopolitical Tensions

 
• By Anju Ghangurde

Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.

Akeso Wins US Approval For PD-1 Antibody In NPC, Partly On US Data

 
• By Dexter Jie Yan

Akeso’s penpulimab will be the second to hit the US market for nasopharyngeal carcinoma, but the first to win FDA approval for the indication based on clinical findings in US patients.